Ascendis Pharma (ASND) Tops Q1 EPS by 68c

Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of (EUR1.98), EUR0.68 better than the analyst estimate of (EUR2.66). Revenue for the quarter came in at EUR28.97 million versus the consensus estimate of EUR21.15 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• Ascendis Pharma (ASND) call put ratio 1 call to 1 put a share price down 12.6%
• Analysts eye Intuit investor day for signs estimates have troughed